{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:53:47Z","timestamp":1791230027368,"version":"4.1.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming an increasingly pressing global health challenge, with increasing mortality rates showing an upward trend. Two million deaths occur annually from cirrhosis and liver cancer together each year. Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), key effectors of the Hippo signaling pathway, critically regulate tissue homeostasis and disease progression in the liver. While initial studies have shown that YAP expression is normally restricted to cholangiocytes in healthy livers, the activation of YAP\/TAZ is observed in other hepatic cells during chronic liver disease. The disease-driven dysregulation of YAP\/TAZ appears to be a critical element in the MASLD progression, contributing to hepatocyte dysfunction, inflammation, and fibrosis. In this study, we focused on the complex roles of YAP\/TAZ in MASLD and explored how the YAP\/TAZ dysregulation of YAP\/TAZ drives steatosis, inflammation, fibrosis, and cirrhosis. Finally, the cell-type-specific functions of YAP\/TAZ in different types of hepatic cells, such as hepatocytes, hepatic stellate cells, hepatic macrophages, and biliary epithelial cells are discussed, highlighting the multifaceted impact of YAP\/TAZ on liver physiology and pathology.<\/jats:p>","DOI":"10.1007\/s12272-024-01501-5","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T07:03:42Z","timestamp":1718780622000},"page":"558-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Interplay between YAP\/TAZ and metabolic dysfunction-associated steatotic liver disease progression"],"prefix":"10.1007","volume":"47","author":[{"given":"Na Young","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeung Gi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-1105","authenticated-orcid":false,"given":"Ja Hyun","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"1501_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/wdev.340","volume":"8","author":"A Abu Rmilah","year":"2019","unstructured":"Abu Rmilah A, Zhou W, Nelson E, Lin L, Amiot B, Nyberg SL (2019) Understanding the marvels behind liver regeneration. Wiley Interdiscip Rev Dev Biol 8:e340. https:\/\/doi.org\/10.1002\/wdev.340","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"1501_CR2","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1093\/hmg\/ddaa197","volume":"29","author":"M Airik","year":"2020","unstructured":"Airik M, Schuler M, Mccourt B, Weiss AC, Herdman N, Ludtke TH, Widmeier E, Stolz DB, Nejak-Bowen KN, Yimlamai D, Wu YL, Kispert A, Airik R, Hildebrandt F (2020) Loss of Anks6 leads to YAP deficiency and liver abnormalities. Hum Mol Genet 29:3064\u20133080. https:\/\/doi.org\/10.1093\/hmg\/ddaa197","journal-title":"Hum Mol Genet"},{"key":"1501_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS (2019) Burden of liver diseases in the world. J Hepatol 70:151\u2013171. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.014","journal-title":"J Hepatol"},{"key":"1501_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1101\/gad.274167.115","volume":"30","author":"Y Aylon","year":"2016","unstructured":"Aylon Y, Gershoni A, Rotkopf R, Biton IE, Porat Z, Koh AP, Sun X, Lee Y, Fiel MI, Hoshida Y, Friedman SL, Johnson RL, Oren M (2016) The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes Dev 30:786\u2013797. https:\/\/doi.org\/10.1101\/gad.274167.115","journal-title":"Genes Dev"},{"key":"1501_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/hep.31120","volume":"72","author":"A Bisso","year":"2020","unstructured":"Bisso A, Filipuzzi M, Gamarra Figueroa GP, Brumana G, Biagioni F, Doni M, Ceccotti G, Tanaskovic N, Morelli MJ, Pendino V, Chiacchiera F, Pasini D, Olivero D, Campaner S, Sabo A, Amati B (2020) Cooperation between MYC and beta-Catenin in liver tumorigenesis requires Yap\/Taz. Hepatology 72:1430\u20131443. https:\/\/doi.org\/10.1002\/hep.31120","journal-title":"Hepatology"},{"key":"1501_CR6","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1038\/s41388-021-01950-y","volume":"40","author":"MK Brahma","year":"2021","unstructured":"Brahma MK, Gilglioni EH, Zhou L, Trepo E, Chen P, Gurzov EN (2021) Oxidative stress in obesity-associated hepatocellular carcinoma: sources signaling and therapeutic challenges. Oncogene 40:5155\u20135167. https:\/\/doi.org\/10.1038\/s41388-021-01950-y","journal-title":"Oncogene"},{"key":"1501_CR7","doi-asserted-by":"publisher","first-page":"21387","DOI":"10.1038\/srep21387","volume":"6","author":"SR Caliari","year":"2016","unstructured":"Caliari SR, Perepelyuk M, Cosgrove BD, Tsai SJ, Lee GY, Mauck RL, Wells RG, Burdick JA (2016) Stiffening hydrogels for investigating the dynamics of hepatic stellate cell mechanotransduction during myofibroblast activation. Sci Rep 6:21387. https:\/\/doi.org\/10.1038\/srep21387","journal-title":"Sci Rep"},{"key":"1501_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/ncb2756","volume":"15","author":"F Calvo","year":"2013","unstructured":"Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, Charras G, Sahai E (2013) Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15:637\u2013646. https:\/\/doi.org\/10.1038\/ncb2756","journal-title":"Nat Cell Biol"},{"key":"1501_CR9","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1016\/j.celrep.2017.02.041","volume":"18","author":"S Chakraborty","year":"2017","unstructured":"Chakraborty S, Njah K, Pobbati AV, Lim YB, Raju A, Lakshmanan M, Tergaonkar V, Lim CT, Hong W (2017) Agrin as a mechanotransduction signal regulating YAP through the hippo pathway. Cell Rep 18:2464\u20132479. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.041","journal-title":"Cell Rep"},{"key":"1501_CR10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1101\/gad.1865310","volume":"24","author":"L Chen","year":"2010","unstructured":"Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W, Song H (2010) Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev 24:290\u2013300. https:\/\/doi.org\/10.1101\/gad.1865310","journal-title":"Genes Dev"},{"key":"1501_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12944-017-0572-9","volume":"16","author":"Z Chen","year":"2017","unstructured":"Chen Z, Yu R, Xiong Y, Du F, Zhu S (2017) A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis 16:203. https:\/\/doi.org\/10.1186\/s12944-017-0572-9","journal-title":"Lipids Health Dis"},{"key":"1501_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12072-017-9841-y","volume":"12","author":"P Chen","year":"2018","unstructured":"Chen P, Luo Q, Huang C, Gao Q, Li L, Chen J, Chen B, Liu W, Zeng W, Chen Z (2018) Pathogenesis of non-alcoholic fatty liver disease mediated by YAP. Hepatol Int 12:26\u201336. https:\/\/doi.org\/10.1007\/s12072-017-9841-y","journal-title":"Hepatol Int"},{"key":"1501_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3727\/105221618X15156018385515","volume":"18","author":"JYL Chiang","year":"2018","unstructured":"Chiang JYL, Ferrell JM (2018) Bile acid metabolism in liver pathobiology. Gene Expr 18:71\u201387. https:\/\/doi.org\/10.3727\/105221618X15156018385515","journal-title":"Gene Expr"},{"key":"1501_CR14","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1002\/hep.32000","volume":"74","author":"K Cho","year":"2021","unstructured":"Cho K, Ro SW, Lee HW, Moon H, Han S, Kim HR, Ahn SH, Park JY, Kim DY (2021) YAP\/TAZ suppress drug penetration into hepatocellular carcinoma through stromal activation. Hepatology 74:2605\u20132621. https:\/\/doi.org\/10.1002\/hep.32000","journal-title":"Hepatology"},{"key":"1501_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13046-022-02394-2","volume":"41","author":"A Cigliano","year":"2022","unstructured":"Cigliano A, Zhang S, Ribback S, Steinmann S, Sini M, Ament CE, Utpatel K, Song X, Wang J, Pilo MG, Berger F, Wang H, Tao J, Li X, Pes GM, Mancarella S, Giannelli G, Dombrowski F, Evert M, Calvisi DF, Chen X, Evert K (2022) The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease. J Exp Clin Cancer Res 41:192. https:\/\/doi.org\/10.1186\/s13046-022-02394-2","journal-title":"J Exp Clin Cancer Res"},{"key":"1501_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jcmgh.2020.09.014","volume":"11","author":"F Daoud","year":"2021","unstructured":"Daoud F, Holmberg J, Alajbegovic A, Grossi M, Rippe C, Sward K, Albinsson S (2021) Inducible deletion of YAP and TAZ in adult mouse smooth muscle causes rapid and lethal colonic pseudo-obstruction. Cell Mol Gastroenterol Hepatol 11:623\u2013637. https:\/\/doi.org\/10.1016\/j.jcmgh.2020.09.014","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1501_CR17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41419-021-04377-1","volume":"12","author":"V De Smet","year":"2021","unstructured":"De Smet V, Eysackers N, Merens V, Kazemzadeh Dastjerd M, Halder G, Verhulst S, Mannaerts I, Van Grunsven LA (2021) Initiation of hepatic stellate cell activation extends into chronic liver disease. Cell Death Dis 12:1110. https:\/\/doi.org\/10.1038\/s41419-021-04377-1","journal-title":"Cell Death Dis"},{"key":"1501_CR18","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","volume":"28","author":"AJ Debacker","year":"2020","unstructured":"Debacker AJ, Voutila J, Catley M, Blakey D, Habib N (2020) Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther 28:1759\u20131771. https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.015","journal-title":"Mol Ther"},{"key":"1501_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12967-022-03768-y","volume":"20","author":"B Deng","year":"2022","unstructured":"Deng B, Zhao Z, Kong W, Han C, Shen X, Zhou C (2022) Biological role of matrix stiffness in tumor growth and treatment. J Transl Med 20:540. https:\/\/doi.org\/10.1186\/s12967-022-03768-y","journal-title":"J Transl Med"},{"key":"1501_CR20","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","volume":"130","author":"J Dong","year":"2007","unstructured":"Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130:1120\u20131133. https:\/\/doi.org\/10.1016\/j.cell.2007.07.019","journal-title":"Cell"},{"issue":"1465\u20131479","key":"1501_CR21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.12.022","volume":"154","author":"K Du","year":"2018","unstructured":"Du K, Hyun J, Premont RT, Choi SS, Michelotti GA, Swiderska-Syn M, Dalton GD, Thelen E, Rizi BS, Jung Y, Diehl AM (2018) Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology 154(1465\u20131479):e13. https:\/\/doi.org\/10.1053\/j.gastro.2017.12.022","journal-title":"Gastroenterology"},{"key":"1501_CR22","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1097\/HEP.0000000000000326","volume":"77","author":"K Du","year":"2023","unstructured":"Du K, Maeso-Diaz R, Oh SH, Wang E, Chen T, Pan C, Xiang K, Dutta RK, Wang XF, Chi JT, Diehl AM (2023) Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology 77:1998\u20132015. https:\/\/doi.org\/10.1097\/HEP.0000000000000326","journal-title":"Hepatology"},{"key":"1501_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S (2011) Role of YAP\/TAZ in mechanotransduction. Nature 474:179\u2013183. https:\/\/doi.org\/10.1038\/nature10137","journal-title":"Nature"},{"key":"1501_CR24","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jhep.2023.08.018","volume":"79","author":"F Ebrahimi","year":"2023","unstructured":"Ebrahimi F, Hagstrom H, Sun J, Bergman D, Shang Y, Yang W, Roelstraete B, Ludvigsson JF (2023) Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: nationwide multigenerational cohort study. J Hepatol 79:1374\u20131384. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.018","journal-title":"J Hepatol"},{"issue":"1999\u20132014","key":"1501_CR25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"Eslam M, Sanyal AJ, George J & International Consensus P","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J & International Consensus P (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(1999\u20132014):e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"key":"1501_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41419-019-1779-7","volume":"10","author":"G Fabris","year":"2019","unstructured":"Fabris G, Dumortier O, Pisani DF, Gautier N, Van Obberghen E (2019) Amino acid-induced regulation of hepatocyte growth: possible role of Drosha. Cell Death Dis 10:566. https:\/\/doi.org\/10.1038\/s41419-019-1779-7","journal-title":"Cell Death Dis"},{"key":"1501_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-06991-9","volume":"626","author":"W Fan","year":"2024","unstructured":"Fan W, Adebowale K, Vancza L, Li Y, Rabbi MF, Kunimoto K, Chen D, Mozes G, Chiu DK, Li Y, Tao J, Wei Y, Adeniji N, Brunsing RL, Dhanasekaran R, Singhi A, Geller D, Lo SH, Hodgson L, Engleman EG, Charville GW, Charu V, Monga SP, Kim T, Wells RG, Chaudhuri O, Torok NJ (2024) Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver. Nature 626:635\u2013642. https:\/\/doi.org\/10.1038\/s41586-023-06991-9","journal-title":"Nature"},{"key":"1501_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cmet.2012.03.004","volume":"15","author":"RV Farese Jr","year":"2012","unstructured":"Farese RV Jr, Zechner R, Newgard CB, Walther TC (2012) The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab 15:570\u2013573. https:\/\/doi.org\/10.1016\/j.cmet.2012.03.004","journal-title":"Cell Metab"},{"key":"1501_CR29","doi-asserted-by":"publisher","first-page":"19290","DOI":"10.1074\/jbc.RA118.005457","volume":"293","author":"Y Feng","year":"2018","unstructured":"Feng Y, Liang Y, Zhu X, Wang M, Gui Y, Lu Q, Gu M, Xue X, Sun X, He W, Yang J, Johnson RL, Dai C (2018) The signaling protein Wnt5a promotes TGFbeta1-mediated macrophage polarization and kidney fibrosis by inducing the transcriptional regulators Yap\/Taz. J Biol Chem 293:19290\u201319302. https:\/\/doi.org\/10.1074\/jbc.RA118.005457","journal-title":"J Biol Chem"},{"key":"1501_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4093\/dmj.2023.0240","volume":"48","author":"SL Friedman","year":"2024","unstructured":"Friedman SL (2024) Hepatic fibrosis and cancer: the silent threats of metabolic syndrome. Diabetes Metab J 48:161\u2013169. https:\/\/doi.org\/10.4093\/dmj.2023.0240","journal-title":"Diabetes Metab J"},{"key":"1501_CR31","doi-asserted-by":"publisher","first-page":"e14351","DOI":"10.15252\/emmm.202114351","volume":"13","author":"R Gao","year":"2021","unstructured":"Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S, Piscuoglio S, Dill MT, Camargo FD, Christofori G, Tang F (2021) YAP\/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med 13:e14351. https:\/\/doi.org\/10.15252\/emmm.202114351","journal-title":"EMBO Mol Med"},{"key":"1501_CR32","doi-asserted-by":"publisher","first-page":"ebj4743","DOI":"10.1126\/scisignal.abj4743","volume":"15","author":"JP Guegan","year":"2022","unstructured":"Guegan JP, Lapouge M, Voisin L, Saba-El-Leil MK, Tanguay PL, Levesque K, Bregeon J, Mes-Masson AM, Lamarre D, Haibe-Kains B, Trinh VQ, Soucy G, Bilodeau M, Meloche S (2022) Signaling by the tyrosine kinase Yes promotes liver cancer development. Sci Signal 15:ebj4743. https:\/\/doi.org\/10.1126\/scisignal.abj4743","journal-title":"Sci Signal"},{"key":"1501_CR33","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1002\/jcb.25117","volume":"116","author":"Y Guo","year":"2015","unstructured":"Guo Y, Pan Q, Zhang J, Xu X, Liu X, Wang Q, Yi R, Xie X, Yao L, Liu W, Shen L (2015) Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma. J Cell Biochem 116:2465\u20132475. https:\/\/doi.org\/10.1002\/jcb.25117","journal-title":"J Cell Biochem"},{"key":"1501_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6296","author":"AJ Haak","year":"2019","unstructured":"Haak AJ, Kostallari E, Sicard D, Ligresti G, Choi KM, Caporarello N, Jones DL, Tan Q, Meridew J, Diaz Espinosa AM, Aravamudhan A, Maiers JL, Britt RD Jr, Roden AC, Pabelick CM, Prakash YS, Nouraie SM, Li X, Zhang Y, Kass DJ, Lagares D, Tager AM, Varelas X, Shah VH, Tschumperlin DJ (2019) Selective YAP\/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aau6296","journal-title":"Sci Transl Med"},{"key":"1501_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/261365","volume":"2014","author":"SX Han","year":"2014","unstructured":"Han SX, Bai E, Jin GH, He CC, Guo XJ, Wang LJ, Li M, Ying X, Zhu Q (2014) Expression and clinical significance of YAP TAZ and AREG in hepatocellular carcinoma. J Immunol Res 2014:261365. https:\/\/doi.org\/10.1155\/2014\/261365","journal-title":"J Immunol Res"},{"key":"1501_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112733","author":"S Han","year":"2022","unstructured":"Han S, Lim JY, Cho K, Lee HW, Park JY, Ro SW, Kim KS, Seo HR, Kim DY (2022) Anti-cancer effects of YAP inhibitor (CA3) in combination with Sorafenib against hepatocellular carcinoma (HCC) in patient-derived multicellular tumor spheroid models (MCTS). Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14112733","journal-title":"Cancers (Basel)"},{"key":"1501_CR37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericas JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V, Investigators M-N (2024) A phase 3 randomized controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390:497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"1501_CR38","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1073\/pnas.0605266104","volume":"104","author":"Z Hossain","year":"2007","unstructured":"Hossain Z, Ali SM, Ko HL, Xu J, Ng CP, Guo K, Qi Z, Ponniah S, Hong W, Hunziker W (2007) Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proc Natl Acad Sci USA 104:1631\u20131636. https:\/\/doi.org\/10.1073\/pnas.0605266104","journal-title":"Proc Natl Acad Sci USA"},{"key":"1501_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.gastha.2022.07.015","volume":"2","author":"HR Hrncir","year":"2023","unstructured":"Hrncir HR, Gracz AD (2023) Cellular and transcriptional heterogeneity in the intrahepatic biliary epithelium. Gastro Hep Adv 2:108\u2013120. https:\/\/doi.org\/10.1016\/j.gastha.2022.07.015","journal-title":"Gastro Hep Adv"},{"key":"1501_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060600","author":"HD Huh","year":"2019","unstructured":"Huh HD, Kim DH, Jeong HS, Park HW (2019) Regulation of TEAD transcription factors in cancer biology. Cells. https:\/\/doi.org\/10.3390\/cells8060600","journal-title":"Cells"},{"key":"1501_CR41","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1136\/gutjnl-2018-317603","volume":"68","author":"J Hyun","year":"2019","unstructured":"Hyun J, Oh SH, Premont RT, Guy CD, Berg CL, Diehl AM (2019) Dysregulated activation of fetal liver programme in acute liver failure. Gut 68:1076\u20131087. https:\/\/doi.org\/10.1136\/gutjnl-2018-317603","journal-title":"Gut"},{"key":"1501_CR42","doi-asserted-by":"publisher","first-page":"E3297","DOI":"10.1073\/pnas.1400062111","volume":"111","author":"K Iwaisako","year":"2014","unstructured":"Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, Liu X, Xu J, Wang P, Paik YH, Meng F, Asagiri M, Murray LA, Hofmann AF, Iida T, Glass CK, Brenner DA, Kisseleva T (2014) Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci USA 111:E3297\u2013E3305. https:\/\/doi.org\/10.1073\/pnas.1400062111","journal-title":"Proc Natl Acad Sci USA"},{"key":"1501_CR43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12967-023-04189-1","volume":"21","author":"C Jin","year":"2023","unstructured":"Jin C, Luo Y, Liang Z, Li X, Kolat D, Zhao L, Xiong W (2023) Crucial role of the transcription factors family activator protein 2 in cancer: current clue and views. J Transl Med 21:371. https:\/\/doi.org\/10.1186\/s12967-023-04189-1","journal-title":"J Transl Med"},{"key":"1501_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115561","volume":"167","author":"F Jing","year":"2023","unstructured":"Jing F, Li X, Jiang H, Sun J, Guo Q (2023) Combating drug resistance in hepatocellular carcinoma: no awareness today no action tomorrow. Biomed Pharmacother 167:115561. https:\/\/doi.org\/10.1016\/j.biopha.2023.115561","journal-title":"Biomed Pharmacother"},{"key":"1501_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1172\/JCI88486","volume":"127","author":"W Kim","year":"2017","unstructured":"Kim W, Khan SK, Gvozdenovic-Jeremic J, Kim Y, Dahlman J, Kim H, Park O, Ishitani T, Jho EH, Gao B, Yang Y (2017) Hippo signaling interactions with Wnt\/beta-catenin and Notch signaling repress liver tumorigenesis. J Clin Invest 127:137\u2013152. https:\/\/doi.org\/10.1172\/JCI88486","journal-title":"J Clin Invest"},{"key":"1501_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1101\/gad.331546.119","volume":"34","author":"JH Koo","year":"2020","unstructured":"Koo JH, Plouffe SW, Meng Z, Lee DH, Yang D, Lim DS, Wang CY, Guan KL (2020) Induction of AP-1 by YAP\/TAZ contributes to cell proliferation and organ growth. Genes Dev 34:72\u201386. https:\/\/doi.org\/10.1101\/gad.331546.119","journal-title":"Genes Dev"},{"key":"1501_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41419-024-06448-5","volume":"15","author":"A Kwon","year":"2024","unstructured":"Kwon A, Lee NY, Yu JH, Choi MG, Park J, Koo JH (2024) Mitochondrial stress activates YAP\/TAZ through RhoA oxidation to promote liver injury. Cell Death Dis 15:51. https:\/\/doi.org\/10.1038\/s41419-024-06448-5","journal-title":"Cell Death Dis"},{"key":"1501_CR48","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1038\/s41467-018-07338-z","volume":"9","author":"YA Lee","year":"2018","unstructured":"Lee YA, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML, Fujiwara N, Goossens N, Chou HI, Parvin-Nejad FP, Khambu B, Kramer EGM, Gordon R, Pfleger C, Germain D, John GR, Campbell KN, Yue Z, Yin XM, Cuervo AM, Czaja MJ, Fiel MI, Hoshida Y, Friedman SL (2018) Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nat Commun 9:4962. https:\/\/doi.org\/10.1038\/s41467-018-07338-z","journal-title":"Nat Commun"},{"key":"1501_CR49","doi-asserted-by":"publisher","first-page":"6699","DOI":"10.1038\/s41467-023-42360-w","volume":"14","author":"CON Leung","year":"2023","unstructured":"Leung CON, Yang Y, Leung RWH, So KKH, Guo HJ, Lei MML, Muliawan GK, Gao Y, Yu QQ, Yun JP, Ma S, Zhao Q, Lee TKW (2023) Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Nat Commun 14:6699. https:\/\/doi.org\/10.1038\/s41467-023-42360-w","journal-title":"Nat Commun"},{"key":"1501_CR50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1478-3231.2011.02646.x","volume":"32","author":"H Li","year":"2012","unstructured":"Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, Ranganathan S, Apte U (2012) Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int 32:38\u201347. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02646.x","journal-title":"Liver Int"},{"key":"1501_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306827","author":"K Li","year":"2024","unstructured":"Li K, Zhang J, Lyu H, Yang J, Wei W, Wang Y, Luo H, Zhang Y, Jiang X, Yi H, Wang M, Zhang C, Wu K, Xiao L, Wen W, Xu H, Li G, Wan Y, Yang F, Yang R, Fu X, Qin B, Zhou Z, Zhang H, Lee MH (2024) CSN6-SPOP-HMGCS1 axis promotes hepatocellular carcinoma progression via YAP1 activation. Adv Sci (Weinh). https:\/\/doi.org\/10.1002\/advs.202306827","journal-title":"Adv Sci (Weinh)"},{"key":"1501_CR52","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2019.05.029","volume":"71","author":"Y Liu","year":"2019","unstructured":"Liu Y, Lu T, Zhang C, Xu J, Xue Z, Busuttil RW, Xu N, Xia Q, Kupiec-Weglinski JW, Ji H (2019) Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury. J Hepatol 71:719\u2013730. https:\/\/doi.org\/10.1016\/j.jhep.2019.05.029","journal-title":"J Hepatol"},{"key":"1501_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00018-024-05126-1","volume":"81","author":"K Liu","year":"2024","unstructured":"Liu K, Wehling L, Wan S, Weiler SME, Toth M, Ibberson D, Marhenke S, Ali A, Lam M, Guo T, Pinna F, Pedrini F, Damle-Vartak A, Dropmann A, Rose F, Colucci S, Cheng W, Bissinger M, Schmitt J, Birner P, Poth T, Angel P, Dooley S, Muckenthaler MU, Longerich T, Vogel A, Heikenwalder M, Schirmacher P, Breuhahn K (2024) Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication. Cell Mol Life Sci 81:115. https:\/\/doi.org\/10.1007\/s00018-024-05126-1","journal-title":"Cell Mol Life Sci"},{"key":"1501_CR54","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1101\/gad.192856.112","volume":"26","author":"Y Liu-Chittenden","year":"2012","unstructured":"Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO, Pan D (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 26:1300\u20131305. https:\/\/doi.org\/10.1101\/gad.192856.112","journal-title":"Genes Dev"},{"key":"1501_CR55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3","journal-title":"Nat Rev Dis Primers"},{"key":"1501_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.205","volume":"50","author":"L Lu","year":"2018","unstructured":"Lu L, Finegold MJ, Johnson RL (2018) Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration. Exp Mol Med 50:e423. https:\/\/doi.org\/10.1038\/emm.2017.205","journal-title":"Exp Mol Med"},{"key":"1501_CR57","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jhep.2015.05.031","volume":"63","author":"MV Machado","year":"2015","unstructured":"Machado MV, Michelotti GA, Pereira TA, Xie G, Premont R, Cortez-Pinto H, Diehl AM (2015) Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J Hepatol 63:962\u2013970. https:\/\/doi.org\/10.1016\/j.jhep.2015.05.031","journal-title":"J Hepatol"},{"key":"1501_CR58","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201798642","author":"D Maglic","year":"2018","unstructured":"Maglic D, Schlegelmilch K, Dost AF, Panero R, Dill MT, Calogero RA, Camargo FD (2018) YAP-TEAD signaling promotes basal cell carcinoma development via a c-JUN\/AP1 axis. EMBO J. https:\/\/doi.org\/10.15252\/embj.201798642","journal-title":"EMBO J"},{"key":"1501_CR59","doi-asserted-by":"publisher","first-page":"F542","DOI":"10.1152\/ajprenal.00201.2007","volume":"294","author":"R Makita","year":"2008","unstructured":"Makita R, Uchijima Y, Nishiyama K, Amano T, Chen Q, Takeuchi T, Mitani A, Nagase T, Yatomi Y, Aburatani H, Nakagawa O, Small EV, Cobo-Stark P, Igarashi P, Murakami M, Tominaga J, Sato T, Asano T, Kurihara Y, Kurihara H (2008) Multiple renal cysts urinary concentration defects and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol 294:F542\u2013F553. https:\/\/doi.org\/10.1152\/ajprenal.00201.2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"1501_CR60","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jhep.2015.04.011","volume":"63","author":"I Mannaerts","year":"2015","unstructured":"Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, Thoen LF, Hoorens A, Reynaert H, Halder G, Van Grunsven LA (2015) The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol 63:679\u2013688. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.011","journal-title":"J Hepatol"},{"key":"1501_CR61","doi-asserted-by":"publisher","first-page":"12502","DOI":"10.1038\/ncomms12502","volume":"7","author":"K Martin","year":"2016","unstructured":"Martin K, Pritchett J, Llewellyn J, Mullan AF, Athwal VS, Dobie R, Harvey E, Zeef L, Farrow S, Streuli C, Henderson NC, Friedman SL, Hanley NA, Piper Hanley K (2016) PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat Commun 7:12502. https:\/\/doi.org\/10.1038\/ncomms12502","journal-title":"Nat Commun"},{"key":"1501_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00915-2","author":"KP Matchett","year":"2024","unstructured":"Matchett KP, Paris J, Teichmann SA, Henderson NC (2024) Spatial genomics: mapping human steatotic liver disease. Nat Rev Gastroenterol Hepatol. https:\/\/doi.org\/10.1038\/s41575-024-00915-2","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1501_CR63","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, Pradere JP, Schwabe RF (2013) Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 4:2823. https:\/\/doi.org\/10.1038\/ncomms3823","journal-title":"Nat Commun"},{"key":"1501_CR64","doi-asserted-by":"publisher","first-page":"16146","DOI":"10.1038\/ncomms16146","volume":"8","author":"N Miyamura","year":"2017","unstructured":"Miyamura N, Hata S, Itoh T, Tanaka M, Nishio M, Itoh M, Ogawa Y, Terai S, Sakaida I, Suzuki A, Miyajima A, Nishina H (2017) Erratum: YAP determines the cell fate of injured mouse hepatocytes in vivo. Nat Commun 8:16146. https:\/\/doi.org\/10.1038\/ncomms16146","journal-title":"Nat Commun"},{"key":"1501_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109310","volume":"36","author":"LM Molina","year":"2021","unstructured":"Molina LM, Zhu J, Li Q, Pradhan-Sundd T, Krutsenko Y, Sayed K, Jenkins N, Vats R, Bhushan B, Ko S, Hu S, Poddar M, Singh S, Tao J, Sundd P, Singhi A, Watkins S, Ma X, Benos PV, Feranchak A, Michalopoulos G, Nejak-Bowen K, Watson A, Bell A, Monga SP (2021) Compensatory hepatic adaptation accompanies permanent absence of intrahepatic biliary network due to YAP1 loss in liver progenitors. Cell Rep 36:109310. https:\/\/doi.org\/10.1016\/j.celrep.2021.109310","journal-title":"Cell Rep"},{"key":"1501_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-0041-1742277","volume":"42","author":"L Molina","year":"2022","unstructured":"Molina L, Nejak-Bowen K, Monga SP (2022) Role of YAP1 signaling in biliary development repair and disease. Semin Liver Dis 42:17\u201333. https:\/\/doi.org\/10.1055\/s-0041-1742277","journal-title":"Semin Liver Dis"},{"key":"1501_CR67","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12885-022-09516-1","volume":"22","author":"H Moon","year":"2022","unstructured":"Moon H, Park H, Chae MJ, Choi HJ, Kim DY, Ro SW (2022) Activated TAZ induces liver cancer in collaboration with EGFR\/HER2 signaling pathways. BMC Cancer 22:423. https:\/\/doi.org\/10.1186\/s12885-022-09516-1","journal-title":"BMC Cancer"},{"key":"1501_CR68","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/hep.30928","volume":"71","author":"M Mooring","year":"2020","unstructured":"Mooring M, Fowl BH, Lum SZC, Liu Y, Yao K, Softic S, Kirchner R, Bernstein A, Singhi AD, Jay DG, Kahn CR, Camargo FD, Yimlamai D (2020) Hepatocyte stress increases expression of Yes-associated protein and transcriptional coactivator With PDZ-binding Motif in hepatocytes to promote parenchymal inflammation and fibrosis. Hepatology 71:1813\u20131830. https:\/\/doi.org\/10.1002\/hep.30928","journal-title":"Hepatology"},{"key":"1501_CR69","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1128\/MCB.26.1.77-87.2006","volume":"26","author":"EM Morin-Kensicki","year":"2006","unstructured":"Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, Alb JG, Magnuson TR, O\u2019neal W & Milgram SL, (2006) Defects in yolk sac vasculogenesis chorioallantoic fusion and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol 26:77\u201387. https:\/\/doi.org\/10.1128\/MCB.26.1.77-87.2006","journal-title":"Mol Cell Biol"},{"key":"1501_CR70","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.aaw9886","volume":"366","author":"IM Moya","year":"2019","unstructured":"Moya IM, Castaldo SA, Van Den Mooter L, Soheily S, Sansores-Garcia L, Jacobs J, Mannaerts I, Xie J, Verboven E, Hillen H, Alguero-Nadal A, Karaman R, Van Haele M, Kowalczyk W, De Waegeneer M, Verhulst S, Karras P, Van Huffel L, Zender L, Marine JC, Roskams T, Johnson R, Aerts S, Van Grunsven LA, Halder G (2019) Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science 366:1029\u20131034. https:\/\/doi.org\/10.1126\/science.aaw9886","journal-title":"Science"},{"key":"1501_CR71","first-page":"167","volume":"11","author":"F Nassir","year":"2015","unstructured":"Nassir F, Rector RS, Hammoud GM, Ibdah JA (2015) Pathogenesis and prevention of hepatic steatosis. Gastroenterol Hepatol (N Y) 11:167\u2013175","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"1501_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113674","author":"S Noguchi","year":"2018","unstructured":"Noguchi S, Saito A, Nagase T (2018) YAP\/TAZ signaling as a molecular link between fibrosis and cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19113674","journal-title":"Int J Mol Sci"},{"key":"1501_CR73","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jhep.2012.10.011","volume":"58","author":"O'hara SP, Tabibian JH, Splinter PL","year":"2013","unstructured":"O\u2019hara SP, Tabibian JH, Splinter PL, Larusso NF, (2013) The dynamic biliary epithelia: molecules pathways and disease. J Hepatol 58:575\u2013582. https:\/\/doi.org\/10.1016\/j.jhep.2012.10.011","journal-title":"J Hepatol"},{"key":"1501_CR74","doi-asserted-by":"publisher","first-page":"17206","DOI":"10.18632\/oncotarget.4043","volume":"6","author":"T Pei","year":"2015","unstructured":"Pei T, Li Y, Wang J, Wang H, Liang Y, Shi H, Sun B, Yin D, Sun J, Song R, Pan S, Sun Y, Jiang H, Zheng T, Liu L (2015) YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget 6:17206\u201320. https:\/\/doi.org\/10.18632\/oncotarget.4043","journal-title":"Oncotarget"},{"key":"1501_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.603926","volume":"11","author":"C Peng","year":"2020","unstructured":"Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX (2020) Non-alcoholic steatohepatitis: a review of its mechanism models and medical treatments. Front Pharmacol 11:603926. https:\/\/doi.org\/10.3389\/fphar.2020.603926","journal-title":"Front Pharmacol"},{"key":"1501_CR76","doi-asserted-by":"publisher","first-page":"11230","DOI":"10.1074\/jbc.RA118.002715","volume":"293","author":"SW Plouffe","year":"2018","unstructured":"Plouffe SW, Lin KC, Moore JL 3rd, Tan FE, Ma S, Ye Z, Qiu Y, Ren B, Guan KL (2018) The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. J Biol Chem 293:11230\u201311240. https:\/\/doi.org\/10.1074\/jbc.RA118.002715","journal-title":"J Biol Chem"},{"key":"1501_CR77","doi-asserted-by":"publisher","DOI":"10.21037\/dmr-21-87","author":"KL Poulsen","year":"2022","unstructured":"Poulsen KL, Cajigas-Du Ross CK, Chaney JK, Nagy LE (2022) Role of the chemokine system in liver fibrosis: a narrative review. Dig Med Res. https:\/\/doi.org\/10.21037\/dmr-21-87","journal-title":"Dig Med Res"},{"key":"1501_CR78","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.tibs.2020.08.012","volume":"46","author":"F Reggiani","year":"2021","unstructured":"Reggiani F, Gobbi G, Ciarrocchi A, Sancisi V (2021) YAP and TAZ are not identical twins. Trends Biochem Sci 46:154\u2013168. https:\/\/doi.org\/10.1016\/j.tibs.2020.08.012","journal-title":"Trends Biochem Sci"},{"key":"1501_CR79","doi-asserted-by":"publisher","first-page":"3140673","DOI":"10.1155\/2017\/3140673","volume":"2017","author":"K Reyes-Gordillo","year":"2017","unstructured":"Reyes-Gordillo K, Shah R, Muriel P (2017) Oxidative stress and inflammation in hepatic diseases: current and future therapy. Oxid Med Cell Longev 2017:3140673. https:\/\/doi.org\/10.1155\/2017\/3140673","journal-title":"Oxid Med Cell Longev"},{"key":"1501_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101170","volume":"4","author":"AM Roy","year":"2023","unstructured":"Roy AM, Iyer R, Chakraborty S (2023) The extracellular matrix in hepatocellular carcinoma: mechanisms and therapeutic vulnerability. Cell Rep Med 4:101170. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101170","journal-title":"Cell Rep Med"},{"key":"1501_CR81","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jcmgh.2021.06.003","volume":"12","author":"S Salloum","year":"2021","unstructured":"Salloum S, Jeyarajan AJ, Kruger AJ, Holmes JA, Shao T, Sojoodi M, Kim MH, Zhuo Z, Shroff SG, Kassa A, Corey KE, Khan SK, Lin W, Alatrakchi N, EaK S, Chung RT (2021) Fatty acids activate the transcriptional coactivator YAP1 to promote liver fibrosis via p38 mitogen-activated protein kinase. Cell Mol Gastroenterol Hepatol 12:1297\u20131310. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.06.003","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1501_CR82","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-15-1447","volume":"22","author":"BH Sohn","year":"2016","unstructured":"Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS (2016) Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clin Cancer Res 22:1256\u20131264. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1447","journal-title":"Clin Cancer Res"},{"key":"1501_CR83","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/hep.30990","volume":"72","author":"K Song","year":"2020","unstructured":"Song K, Kwon H, Han C, Chen W, Zhang J, Ma W, Dash S, Gandhi CR, Wu T (2020) Yes-associated protein in Kupffer cells enhances the production of proinflammatory cytokines and promotes the development of nonalcoholic steatohepatitis. Hepatology 72:72\u201387. https:\/\/doi.org\/10.1002\/hep.30990","journal-title":"Hepatology"},{"key":"1501_CR84","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00535-019-01563-z","volume":"54","author":"T Sugihara","year":"2019","unstructured":"Sugihara T, Isomoto H, Gores G, Smoot R (2019) YAP and the Hippo pathway in cholangiocarcinoma. J Gastroenterol 54:485\u2013491. https:\/\/doi.org\/10.1007\/s00535-019-01563-z","journal-title":"J Gastroenterol"},{"key":"1501_CR85","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000463390","volume":"93","author":"K Sugimachi","year":"2017","unstructured":"Sugimachi K, Nishio M, Aishima S, Kuroda Y, Iguchi T, Komatsu H, Hirata H, Sakimura S, Eguchi H, Bekki Y, Takenaka K, Maehara Y, Suzuki A, Mimori K (2017) Altered expression of Hippo signaling pathway molecules in intrahepatic cholangiocarcinoma. Oncology 93:67\u201374. https:\/\/doi.org\/10.1159\/000463390","journal-title":"Oncology"},{"key":"1501_CR86","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s13402-021-00595-z","volume":"44","author":"T Sun","year":"2021","unstructured":"Sun T, Mao W, Peng H, Wang Q, Jiao L (2021) YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin. Cell Oncol (dordr) 44:689\u2013699. https:\/\/doi.org\/10.1007\/s13402-021-00595-z","journal-title":"Cell Oncol (dordr)"},{"key":"1501_CR87","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cphy.c120019","volume":"3","author":"JH Tabibian","year":"2013","unstructured":"Tabibian JH, Masyuk AI, Masyuk TV, O\u2019hara SP & Larusso NF, (2013) Physiology of cholangiocytes. Compr Physiol 3:541\u2013565. https:\/\/doi.org\/10.1002\/cphy.c120019","journal-title":"Compr Physiol"},{"key":"1501_CR88","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1111\/liv.15048","volume":"41","author":"S Thomann","year":"2021","unstructured":"Thomann S, Weiler SME, Wei T, Sticht C, De La Torre C, Toth M, Rose F, Tang Y, Ritz T, Ball C, Glimm H, Ryschich E, Schirmacher P, Breuhahn K (2021) YAP-induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer. Liver Int 41:3011\u20133023. https:\/\/doi.org\/10.1111\/liv.15048","journal-title":"Liver Int"},{"key":"1501_CR89","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1186\/s12885-021-08794-5","volume":"21","author":"M Toth","year":"2021","unstructured":"Toth M, Wehling L, Thiess L, Rose F, Schmitt J, Weiler SME, Sticht C, De La Torre C, Rausch M, Albrecht T, Grabe N, Duwe L, Andersen JB, Kohler BC, Springfeld C, Mehrabi A, Kulu Y, Schirmacher P, Roessler S, Goeppert B, Breuhahn K (2021) Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer 21:1079. https:\/\/doi.org\/10.1186\/s12885-021-08794-5","journal-title":"BMC Cancer"},{"issue":"1530\u20131542","key":"1501_CR90","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.009","volume":"144","author":"DF Tschaharganeh","year":"2013","unstructured":"Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, Evert M, Fan B, Ribback S, Jiang L, Brozzetti S, Bergmann F, Dombrowski F, Schirmacher P, Calvisi DF, Breuhahn K (2013) Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 144(1530\u20131542):e12. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.009","journal-title":"Gastroenterology"},{"key":"1501_CR91","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14:397\u2013411. https:\/\/doi.org\/10.1038\/nrgastro.2017.38","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1501_CR92","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1101\/gad.888601","volume":"15","author":"A Vassilev","year":"2001","unstructured":"Vassilev A, Kaneko KJ, Shu H, Zhao Y, Depamphilis ML (2001) TEAD\/TEF transcription factors utilize the activation domain of YAP65 a Src\/Yes-associated protein localized in the cytoplasm. Genes Dev 15:1229\u20131241. https:\/\/doi.org\/10.1101\/gad.888601","journal-title":"Genes Dev"},{"key":"1501_CR93","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1053\/j.gastro.2020.10.035","volume":"160","author":"E Verboven","year":"2021","unstructured":"Verboven E, Moya IM, Sansores-Garcia L, Xie J, Hillen H, Kowalczyk W, Vella G, Verhulst S, Castaldo SA, Alguero-Nadal A, Romanelli L, Mercader-Celma C, Souza NA, Soheily S, Van Huffel L, Van Brussel T, Lambrechts D, Roskams T, Lemaigre FP, Bergers G, Van Grunsven LA, Halder G (2021) Regeneration defects in Yap and Taz mutant mouse livers are caused by bile duct disruption and cholestasis. Gastroenterology 160:847\u2013862. https:\/\/doi.org\/10.1053\/j.gastro.2020.10.035","journal-title":"Gastroenterology"},{"key":"1501_CR94","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/aja.1001320404","volume":"132","author":"K Wake","year":"1971","unstructured":"Wake K (1971) \u201cSternzellen\u201d in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat 132:429\u2013462. https:\/\/doi.org\/10.1002\/aja.1001320404","journal-title":"Am J Anat"},{"key":"1501_CR95","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.cmet.2016.09.016","volume":"24","author":"X Wang","year":"2016","unstructured":"Wang X, Zheng Z, Caviglia JM, Corey KE, Herfel TM, Cai B, Masia R, Chung RT, Lefkowitch JH, Schwabe RF, Tabas I (2016) Hepatocyte TAZ\/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab 24:848\u2013862. https:\/\/doi.org\/10.1016\/j.cmet.2016.09.016","journal-title":"Cell Metab"},{"key":"1501_CR96","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/hep4.1405","volume":"3","author":"X Wang","year":"2019","unstructured":"Wang X, Sommerfeld MR, Jahn-Hofmann K, Cai B, Filliol A, Remotti HE, Schwabe RF, Kannt A, Tabas I (2019) A therapeutic silencing RNA targeting hepatocyte TAZ prevents and reverses fibrosis in nonalcoholic steatohepatitis in mice. Hepatol Commun 3:1221\u20131234. https:\/\/doi.org\/10.1002\/hep4.1405","journal-title":"Hepatol Commun"},{"issue":"969\u2013986","key":"1501_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.03.010","volume":"31","author":"X Wang","year":"2020","unstructured":"Wang X, Cai B, Yang X, Sonubi OO, Zheng Z, Ramakrishnan R, Shi H, Valenti L, Pajvani UB, Sandhu J, Infante RE, Radhakrishnan A, Covey DF, Guan KL, Buck J, Levin LR, Tontonoz P, Schwabe RF, Tabas I (2020) Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis. Cell Metab 31(969\u2013986):e7. https:\/\/doi.org\/10.1016\/j.cmet.2020.03.010","journal-title":"Cell Metab"},{"key":"1501_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101165","volume":"31","author":"X Wang","year":"2023","unstructured":"Wang X, Moore MP, Shi H, Miyata Y, Donnelly SK, Radiloff DR, Tabas I (2023) Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers. Mol Ther Methods Clin Dev 31:101165. https:\/\/doi.org\/10.1016\/j.omtm.2023.101165","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1501_CR99","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","volume":"18","author":"Y Wen","year":"2021","unstructured":"Wen Y, Lambrecht J, Ju C, Tacke F (2021) Hepatic macrophages in liver homeostasis and diseases-diversity plasticity and therapeutic opportunities. Cell Mol Immunol 18:45\u201356. https:\/\/doi.org\/10.1038\/s41423-020-00558-8","journal-title":"Cell Mol Immunol"},{"key":"1501_CR100","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.celrep.2013.04.020","volume":"3","author":"H Wu","year":"2013","unstructured":"Wu H, Xiao Y, Zhang S, Ji S, Wei L, Fan F, Geng J, Tian J, Sun X, Qin F, Jin C, Lin J, Yin ZY, Zhang T, Luo L, Li Y, Song S, Lin SC, Deng X, Camargo F, Avruch J, Chen L, Zhou D (2013) The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. Cell Rep 3:1663\u20131677. https:\/\/doi.org\/10.1016\/j.celrep.2013.04.020","journal-title":"Cell Rep"},{"key":"1501_CR101","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1002\/cncr.24495","volume":"115","author":"MZ Xu","year":"2009","unstructured":"Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115:4576\u20134585. https:\/\/doi.org\/10.1002\/cncr.24495","journal-title":"Cancer"},{"key":"1501_CR102","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.7150\/thno.44789","volume":"10","author":"N Yang","year":"2020","unstructured":"Yang N, Chen T, Wang L, Liu R, Niu Y, Sun L, Yao B, Wang Y, Yang W, Liu Q, Tu K, Liu Z (2020) CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Theranostics 10:5790\u20135801. https:\/\/doi.org\/10.7150\/thno.44789","journal-title":"Theranostics"},{"key":"1501_CR103","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jcmgh.2023.01.002","volume":"15","author":"Y Yang","year":"2023","unstructured":"Yang Y, Ni M, Zong R, Yu M, Sun Y, Li J, Chen P, Li C (2023) Targeting Notch1-YAP circuit reprograms macrophage polarization and alleviates acute liver injury in mice. Cell Mol Gastroenterol Hepatol 15:1085\u20131104. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.01.002","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1501_CR104","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cell.2014.03.060","volume":"157","author":"D Yimlamai","year":"2014","unstructured":"Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, Shrestha K, Cahan P, Stanger BZ, Camargo FD (2014) Hippo pathway activity influences liver cell fate. Cell 157:1324\u20131338. https:\/\/doi.org\/10.1016\/j.cell.2014.03.060","journal-title":"Cell"},{"key":"1501_CR105","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.cell.2006.05.030","volume":"125","author":"L Zender","year":"2006","unstructured":"Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125:1253\u20131267. https:\/\/doi.org\/10.1016\/j.cell.2006.05.030","journal-title":"Cell"},{"key":"1501_CR106","doi-asserted-by":"publisher","first-page":"30029","DOI":"10.1038\/srep30029","volume":"6","author":"K Zhang","year":"2016","unstructured":"Zhang K, Chang Y, Shi Z, Han X, Han Y, Yao Q, Hu Z, Cui H, Zheng L, Han T, Hong W (2016) omega-3 PUFAs ameliorate liver fibrosis and inhibit hepatic stellate cells proliferation and activation by promoting YAP\/TAZ degradation. Sci Rep 6:30029. https:\/\/doi.org\/10.1038\/srep30029","journal-title":"Sci Rep"},{"key":"1501_CR107","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41419-020-2264-z","volume":"11","author":"S Zhao","year":"2020","unstructured":"Zhao S, Jiang J, Jing Y, Liu W, Yang X, Hou X, Gao L, Wei L (2020) The concentration of tumor necrosis factor-alpha determines its protective or damaging effect on liver injury by regulating Yap activity. Cell Death Dis 11:70. https:\/\/doi.org\/10.1038\/s41419-020-2264-z","journal-title":"Cell Death Dis"},{"key":"1501_CR108","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s12079-023-00775-6","volume":"17","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Wang H, He T, Ma B, Chen G, Tzeng C (2023) Knockdown of Yap attenuates TAA-induced hepatic fibrosis by interaction with hedgehog signals. J Cell Commun Signal 17:1335\u20131354. https:\/\/doi.org\/10.1007\/s12079-023-00775-6","journal-title":"J Cell Commun Signal"},{"key":"1501_CR109","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12935-019-0898-7","volume":"19","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Wang Y, Zhou W, Chen T, Wu Q, Chutturghoon VK, Lin B, Geng L, Yang Z, Zhou L, Zheng S (2019) YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell Int 19:179. https:\/\/doi.org\/10.1186\/s12935-019-0898-7","journal-title":"Cancer Cell Int"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-024-01501-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-024-01501-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-024-01501-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T14:07:55Z","timestamp":1719842875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-024-01501-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1501"],"URL":"https:\/\/doi.org\/10.1007\/s12272-024-01501-5","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"8 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}